{"schema_version":"secwatch.filing_event.v1","accession":"0001636282-25-000063","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.151337+00:00","generated_at":"2026-05-20T02:57:33.900934+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Spyre Therapeutics stockholders elect three Class III directors at 2025 annual meeting","bullets":["Elected Peter Harwin (38.2M for, 8.0M withheld), Michael Henderson (45.4M for, 0.7M withheld), Sandra Milligan (37.6M for, 8.6M withheld) as Class III directors.","Advisory vote on executive compensation approved: 42.9M for, 3.1M against, 0.1M abstain, 3.1M broker non-votes.","Ratified KPMG LLP as independent auditor for FY2025: 49.2M for, 57k against, 9k abstain, no broker non-votes."],"urls":{"canonical":"https://secwatch.observer/filing/0001636282-25-000063","json":"https://secwatch.observer/filing/0001636282-25-000063.json","markdown":"https://secwatch.observer/filing/0001636282-25-000063.md","text":"https://secwatch.observer/filing/0001636282-25-000063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000163628225000063/0001636282-25-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000163628225000063/syre-20250529.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T02:57:33.900934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}